Infliximab
Infliximab
Biopharmaceutical drug for autoimmune disorders.
No account needed. By playing, you confirm you're 13 or older and agree to the Terms of use.
No owners yet
Category: Empty
- 0 owners
- 0 copies
- 0 pulls
- Wishlisted
- 0
- In 0 albums
- On 0 showcases
- Market listings
- 0
Not sold on the market yet.
Readers' pathsAug 2026 – Oct 2026
Readers go next to
Share of the 2,448 clicks on its links
Behçet's disease
Inflammatory disorder.
8.4%
Monoclonal antibody
Antibodies from clones of the same blood cell.
7.7%
Tumor necrosis factor
Immune system messenger protein which induces inflammation.
7.6%
Adalimumab
Monoclonal antibody pharmaceutical drug.
6.2%
Fusion protein
Protein created by joining other proteins into a single polypeptide.
4.9%
Ankylosing spondylitis
Type of arthritis of the spine.
4.5%
Crohn's disease
Type of inflammatory bowel disease.
4.3%
Drug-induced lupus erythematosus
Medical condition.
3.2%
TNF inhibitor
Class of immunosuppressive drug.
3.1%
Jan Vilček
Slovak immunologist (born 1933).
2.7%
Readers come from
Share of the 1,779 readers arriving from another article
TNF inhibitor
Class of immunosuppressive drug.
11%
Adalimumab
Monoclonal antibody pharmaceutical drug.
9.3%
Psoriasis
Autoimmune diseases of the skin.
7.4%
Celltrion
South Korean biopharmaceutical company.
5.7%
Monoclonal antibody
Antibodies from clones of the same blood cell.
5.5%
Crohn's disease
Type of inflammatory bowel disease.
4.9%
Fungemia
Internal, blood-borne infection by fungi, including yeasts.
3.9%
Ankylosing spondylitis
Type of arthritis of the spine.
3.4%
Guselkumab
Monoclonal antibody.
3.2%
Psoriatic arthritis
Long-term inflammatory arthritis.
2.9%